WO2022191602A1 - 카르니틴살리실레이트를 유효성분으로 포함하는 화장료 조성물 - Google Patents
카르니틴살리실레이트를 유효성분으로 포함하는 화장료 조성물 Download PDFInfo
- Publication number
- WO2022191602A1 WO2022191602A1 PCT/KR2022/003302 KR2022003302W WO2022191602A1 WO 2022191602 A1 WO2022191602 A1 WO 2022191602A1 KR 2022003302 W KR2022003302 W KR 2022003302W WO 2022191602 A1 WO2022191602 A1 WO 2022191602A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carnitine
- salicylate
- cosmetic composition
- skin
- weight
- Prior art date
Links
- 229960001860 salicylate Drugs 0.000 title claims abstract description 203
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 239000002537 cosmetic Substances 0.000 title claims abstract description 89
- 239000004480 active ingredient Substances 0.000 title claims abstract description 22
- 229960004203 carnitine Drugs 0.000 claims abstract description 204
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims abstract description 200
- 210000003491 skin Anatomy 0.000 claims abstract description 83
- 206010015150 Erythema Diseases 0.000 claims abstract description 40
- 231100000321 erythema Toxicity 0.000 claims abstract description 38
- 206010061218 Inflammation Diseases 0.000 claims abstract description 30
- 230000004054 inflammatory process Effects 0.000 claims abstract description 30
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 27
- 206010000496 acne Diseases 0.000 claims abstract description 27
- 210000004927 skin cell Anatomy 0.000 claims abstract description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 37
- 238000004299 exfoliation Methods 0.000 claims description 28
- 230000006872 improvement Effects 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 18
- 229960004889 salicylic acid Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 22
- 230000002378 acidificating effect Effects 0.000 abstract description 14
- 150000002500 ions Chemical class 0.000 abstract description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 196
- 239000000374 eutectic mixture Substances 0.000 description 45
- 230000000694 effects Effects 0.000 description 42
- 102000011782 Keratins Human genes 0.000 description 28
- 108010076876 Keratins Proteins 0.000 description 28
- 239000000463 material Substances 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 18
- 239000006210 lotion Substances 0.000 description 16
- 230000003013 cytotoxicity Effects 0.000 description 15
- 231100000135 cytotoxicity Toxicity 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000006071 cream Substances 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000007794 irritation Effects 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 231100001083 no cytotoxicity Toxicity 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229960003681 gluconolactone Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000007655 standard test method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 235000012209 glucono delta-lactone Nutrition 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 241000021559 Dicerandra Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- IKPNWIGTWUZCKM-JEDNCBNOSA-N acetic acid;(2s)-2-amino-5-[(n'-methylcarbamimidoyl)amino]pentanoic acid Chemical compound CC(O)=O.CN=C(N)NCCC[C@H](N)C(O)=O IKPNWIGTWUZCKM-JEDNCBNOSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010309 melting process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AGAURCCLJKMAEJ-UHFFFAOYSA-N 1,2-bis(2-hydroxyphenyl)ethane-1,2-dione Chemical compound OC1=CC=CC=C1C(=O)C(=O)C1=CC=CC=C1O AGAURCCLJKMAEJ-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Definitions
- the present invention relates to a cosmetic composition
- a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient.
- CA-SA carnitine salicylate
- Skin aging is a process of gradual and continuous physiological changes due to external environmental exposure (exogenous aging) and genetic causes (endogenous aging).
- the skin tissue is always exposed to sunlight among various tissues of the human body, so apoptosis of epidermal stem cells is induced or pigmentation is induced due to aging of melanocytes.
- external stimuli such as sunlight induce inflammation through the promotion of cytokine secretion, which not only causes pain such as erythema, stinging, and itchiness, but also promotes skin aging.
- cytokine secretion which not only causes pain such as erythema, stinging, and itchiness, but also promotes skin aging.
- Various substances for alleviating skin diseases and aging caused by these external stimuli have been used in cosmetics.
- substances such as retinoid, hydroquinone, L-ascorbic acid, and ⁇ -hydroxy acid (AHA) are known to have an effect in relieving aging, and substances such as D-panthenol and glycyrrhizic acid is known to have efficacy in relieving inflammation.
- salicylate also known as ⁇ -hydroxy acid (BHA)
- BHA ⁇ -hydroxy acid
- salicylate exhibits acidity of pH 3.0 or less in aqueous solution, and may cause irritation when repeatedly applied to the skin.
- the Cosmetic Ingredient Review Expert Panel recommends using salicylate in the form of salicylate at a pH of 3.5 or higher, and recommending that it be applied to cosmetics at 3.0% or less.
- salicylate has low solubility in weakly acidic water
- a method of i) changing to salt form, ii) derivatizing, or iii) dissolving in strongly acidic water and then neutralizing to weak acid was devised, but the above three methods were used. When applied, there is a problem that the original bactericidal effect of salicylate is not sufficiently exhibited.
- a cosmetic composition with a high content by improving solubility in water by incorporating salicylic acid into hydroxyalkylated cyclodextrin is disclosed (Korean Patent Publication No. 10-2010-0095447), which contains carnitine and exhibits an acne improvement effect. It is also known that a method of compounding in the skin is known (Republic of Korea Patent No. 10-2307186), and a cosmetic composition containing a salicylic acid derivative inhibits tyrosinase activity to exhibit a skin whitening effect (Republic of Korea Patent Publication No. 10-2017-0076091) ).
- CA-SA carnitine salicylate
- an object of the present invention relates to a cosmetic composition
- a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient.
- CA-SA carnitine salicylate
- the present invention provides a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient.
- CA-SA carnitine salicylate
- the skin improvement comprising the step of treating the skin with a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient, while exhibiting the effect of alleviating acne and exfoliating the dead skin cells, and soothing the skin
- a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient while exhibiting the effect of alleviating acne and exfoliating the dead skin cells, and soothing the skin
- CA-SA carnitine salicylate
- a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient is administered to a subject, thereby exhibiting acne relief and keratin exfoliation effects by improving skin, and at the same time soothing the skin
- CA-SA carnitine salicylate
- a cosmetic that relieves acne and exfoliates skin by improving the skin and at the same time calms inflammation and erythema of the skin; containing carnitine salicylate (CA-SA) as an active ingredient for manufacturing A use of the composition is provided.
- CA-SA carnitine salicylate
- the present invention relates to a cosmetic composition
- a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient.
- CA-SA carnitine salicylate
- the carnitine is 4-trimethylamino-3-hydroxybutyric acid
- L-carnitine, DL-carnitine, hydrochloride salts thereof, and derivatives thereof may be used.
- L-carnitine is used.
- carnitine is a hypoallergenic amino acid exfoliant that exhibits higher efficacy than ⁇ -hydroxy acid (AHA) in mildly acidic and neutral conditions.
- AHA ⁇ -hydroxy acid
- An external preparation for skin showing an acne improvement effect including carnitine, is disclosed (Korean Patent Application Laid-Open No. 10-2010-0095447).
- carnitine as an additional additive as a ceramide synthesis accelerating material, but does not consist of a component having a different mixing ratio and showing main efficacy.
- results of tests on acne bacteria and sensory evaluation are described regarding the acne improvement effect, but objective results based on standard test methods are not presented with respect to the cytotoxicity, keratin exfoliation, alleviation of inflammation and erythema alleviation of external skin preparations. .
- carnitine salicylate (CA-SA) was manufactured and tested for efficacy in vitro and in vivo .
- CA-SA carnitine salicylate
- Salicylic acid which is generally used, has a low solubility in water, so it is difficult to apply it to cosmetics at high concentrations, there is a limitation in the application formulation, and there is a possibility of causing skin irritation. Therefore, it is recommended to use it in the form of salicylate, but there is a limitation in that skin permeability and efficacy are lowered when applied in weak acidity.
- a method of incorporating salicylic acid into a hydroxyalkylated cyclodextrin to improve solubility in water and blending it in a cosmetic composition with a high content is known (Korean Patent No. 10-2307186). Also, a cosmetic composition containing a salicylic acid derivative is tyrosinase It is also known to exhibit a skin whitening effect by inhibiting the activity (Korean Patent Application Laid-Open No. 10-2017-0076091). However, the prior art suggests a cosmetic composition containing salicylic acid as a derivative.
- carnitine salicylate (CA-SA) was manufactured and tested for efficacy in vitro and in vivo .
- CA-SA carnitine salicylate
- a eutectic mixture may be prepared and used in the form of carnitine salicylate (CA-SA) that is ion-paired with carnitine without using salicylic acid in the form of a salt.
- the cosmetic composition according to the present invention includes carnitine salicylate (CA-SA), so it can be prepared under weakly acidic conditions and can exhibit a more improved effect than the original efficacy of each component. Specifically, the skin improvement effect may be improved by 120% or more, 140% or more, or 160% or more compared to a simple mixture.
- the cosmetic composition according to the present invention can improve the stability of the composition by including carnitine salicylate (CA-SA).
- the eutectic mixture refers to a mixture of two or more solid or liquid substances, and two components having a high melting point are mixed so that polar intermolecular dipole-dipole attraction, dipole-induced dipole attraction, intermolecular hydrogen bonding or van der Waals interaction This means that the two components form a complex. That is, the bond of a eutectic mixture refers to an intermolecular bond (formation of a eutectic mixture) formed in a state in which individual unique molecular structures are maintained based on hydrogen bonds and intermolecular bonds due to partial charges of molecules.
- the eutectic mixture may be combined with compounds having polarity to form a eutectic mixture.
- the compound having the polarity may be a polar molecule or a charged molecule.
- the ratio between the substances required for the eutectic mixture may be determined according to the charge of the molecules of the components constituting the eutectic mixture, the type and number of functional groups the molecule has, and the polarity of the molecule or functional group. In addition, the ratio between substances required for the eutectic mixture may be determined according to the size or similarity of the molecules.
- carnitine salicylate for carnitine salicylate (CA-SA), the ratio between substances required for the eutectic mixture was determined according to the charge and functional group possessed by carnitine and salicylate molecules, and the polarity of the molecule or functional group.
- Carnitine and salicylate can form a eutectic mixture due to the dipole bonding by the partial charge of a specific functional group, and through their chemical structures, they can form a eutectic mixture at a molar ratio in the above range.
- the carnitine salicylate may preferably be a transparent phase without a precipitate when left still at a low temperature. More specifically, it may be that no precipitate is formed even if it is left at 0° C. for 3 weeks, 4 weeks, 5 weeks, or 6 weeks or more.
- the cosmetic composition may be in the form of a general emulsified formulation and a solubilized formulation.
- a lotion such as a softening lotion or nourishing lotion
- a lotion such as a facial lotion and body lotion
- a cream such as a nourishing cream, a moisture cream, an eye cream, an essence, a cosmetic ointment, a balm, a spray, a gel, a pack, a sunscreen , makeup base, liquid type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, cleansing agent such as cleansing foam, soap, body wash, and the like.
- the cosmetic includes a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetology such as other ingredients of
- the cosmetic formulation may include a relatively high concentration of the composition of the present invention in the case of a wash-off type cosmetic such as a makeup remover or a detergent in which the active ingredient stays on the skin within a short period of time.
- a wash-off type cosmetic such as a makeup remover or a detergent
- the composition of the present invention at a lower concentration than the wash-off type cosmetics. would be free to include.
- 0.01 to 20 parts by weight of carnitine salicylate (CA-SA), for example, 0.01 to 20 parts by weight, based on the total weight of the composition of the present invention , 0.01 to 1.2 parts by weight, 0.01 to 1.8 parts by weight, 0.01 to 2.5 parts by weight, 0.01 to 4.7 parts by weight, 0.1 to 7.3 parts by weight, 0.01 to 10 parts by weight, 1.2 to 20 parts by weight, or 1.8 to 10 parts by weight.
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- Each of the above-mentioned ingredients included in the cosmetic composition according to the present invention may be included in the cosmetic composition of the present invention within a range that does not exceed the maximum amount prescribed in the cosmetic safety standards for each country.
- the present invention provides a method for preparing a cosmetic composition comprising carnitine salicylate (CA-SA).
- preparing a mixture of carnitine and salicylic acid preparing carnitine salicylate (CA-SA) by stirring the mixture of carnitine and salicylic acid at 50° C. to 70° C.; and preparing a cosmetic composition by adding the carnitine salicylate (CA-SA).
- CA-SA carnitine salicylate
- the step of preparing the mixture of carnitine and salicylic acid may include adding purified water.
- the temperature is less than 50° C., the eutectic mixing is not sufficiently achieved, and if it exceeds 70° C., the eutectic mixture is broken, thereby reducing the effect of the eutectic mixture.
- the preparing of the carnitine salicylate may include homogenizing the mixture using a homogenizer. At this time, it may include a process of homogenizing the eutectic mixture until it becomes a colorless or light brown transparent phase. Thereafter, additional purification may be omitted.
- the components constituting the eutectic mixture are uniformly mixed under the homogenization conditions as described above, so that the skin improvement effect of the eutectic mixture as described above, hypoallergenicity to the skin, and excellent formulation stability can be realized.
- the liquid state and transparency are maintained even through a cooling process.
- the eutectic mixture prepared as described above is uniformly present without phase separation even at a very low temperature, for example, a temperature below 0° C., thereby maintaining a transparent liquid phase.
- the eutectic mixture may be maintained without breaking its bond even by repeating the solidification and melting processes.
- the step of preparing the carnitine salicylate is performed at a pH of 3.0 to 7.0. It is sufficiently dissolved within the acidity range and the efficacy can be maintained.
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- the cosmetic composition according to the present invention contains carnitine salicylate (CA-SA) as an active ingredient, thereby exhibiting acne relief and keratin exfoliation efficacy as a skin improvement material by ion pairing of carnitine and salicylate in weakly acidic conditions.
- CA-SA carnitine salicylate
- FIG. 1 is a macroscopic and chemical analysis result of carnitine salicylate (CA-SA) according to the present invention.
- 1a is the result of confirming the macroscopic stability according to the molar ratio of carnitine salicylate (CA-SA)
- FIG. 1b is a 1H NMR spectrum of carnitine
- FIG. 1c is a 1H NMR spectrum of salicylate
- FIG. 1d is carnitine salicil 1H NMR spectrum of lactate (CA-SA)
- FIG. 1E is an IR spectrum of carnitine, salicylate, and carnitine salicylate (CA-SA).
- FIG. 3 is an in vivo efficacy confirmation result of carnitine salicylate (CA-SA) according to the present invention.
- Figure 3a is the result of confirming the exfoliating effect of the cosmetic composition containing carnitine salicylate (CA-SA)
- Figure 3b is the result of confirming the erythema alleviation effect of the cosmetic composition containing carnitine salicylate (CA-SA) to be.
- the present invention relates to a cosmetic composition
- a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient.
- CA-SA carnitine salicylate
- the carnitine is 4-trimethylamino-3-hydroxybutyric acid
- L-carnitine, DL-carnitine, hydrochloride salts thereof, and derivatives thereof may be used.
- L-carnitine is used.
- carnitine is a hypoallergenic amino acid exfoliant that exhibits higher efficacy than ⁇ -hydroxy acid (AHA) in mildly acidic and neutral conditions.
- AHA ⁇ -hydroxy acid
- An external preparation for skin showing an acne improvement effect including carnitine, is disclosed (Korean Patent Application Laid-Open No. 10-2010-0095447).
- carnitine as an additional additive as a ceramide synthesis accelerating material, but does not consist of a component having a different mixing ratio and showing main efficacy.
- results of tests on acne bacteria and sensory evaluation are described regarding the acne improvement effect, but objective results based on standard test methods are not presented with respect to the cytotoxicity, keratin exfoliation, alleviation of inflammation and erythema alleviation of external skin preparations. .
- carnitine salicylate (CA-SA) was manufactured and tested for efficacy in vitro and in vivo .
- CA-SA carnitine salicylate
- Salicylic acid which is generally used, has a low solubility in water, so it is difficult to apply it to cosmetics at high concentrations, there is a limitation in the application formulation, and there is a possibility of causing skin irritation. Therefore, it is recommended to use it in the form of salicylate, but there is a limitation in that skin permeability and efficacy are lowered when applied in weak acidity.
- a method of incorporating salicylic acid into a hydroxyalkylated cyclodextrin to improve solubility in water and blending it in a cosmetic composition with a high content is known (Korean Patent No. 10-2307186). Also, a cosmetic composition containing a salicylic acid derivative is tyrosinase It is also known to exhibit a skin whitening effect by inhibiting the activity (Korean Patent Application Laid-Open No. 10-2017-0076091). However, the prior art suggests a cosmetic composition containing salicylic acid as a derivative.
- carnitine salicylate (CA-SA) was manufactured and tested for efficacy in vitro and in vivo .
- CA-SA carnitine salicylate
- a eutectic mixture may be prepared and used in the form of carnitine salicylate (CA-SA) that is ion-paired with carnitine without using salicylic acid in the form of a salt.
- the cosmetic composition according to the present invention includes carnitine salicylate (CA-SA), so it can be prepared under weakly acidic conditions and can exhibit a more improved effect than the original efficacy of each component. Specifically, the skin improvement effect may be improved by 120% or more, 140% or more, or 160% or more compared to a simple mixture.
- the cosmetic composition according to the present invention can improve the stability of the composition by including carnitine salicylate (CA-SA).
- the eutectic mixture refers to a mixture of two or more solid or liquid substances, and two components having a high melting point are mixed so that polar intermolecular dipole-dipole attraction, dipole-induced dipole attraction, intermolecular hydrogen bonding or van der Waals interaction This means that the two components form a complex. That is, the bond of a eutectic mixture refers to an intermolecular bond (formation of a eutectic mixture) formed in a state in which individual unique molecular structures are maintained based on hydrogen bonds and intermolecular bonds due to partial charges of molecules.
- the eutectic mixture may be combined with compounds having polarity to form a eutectic mixture.
- the compound having the polarity may be a polar molecule or a charged molecule.
- the ratio between the substances required for the eutectic mixture may be determined according to the charge of the molecules of the components constituting the eutectic mixture, the type and number of functional groups the molecule has, and the polarity of the molecule or functional group. In addition, the ratio between substances required for the eutectic mixture may be determined according to the size or similarity of the molecules.
- carnitine salicylate for carnitine salicylate (CA-SA), the ratio between substances required for the eutectic mixture was determined according to the charge and functional group possessed by carnitine and salicylate molecules, and the polarity of the molecule or functional group.
- Carnitine and salicylate can form a eutectic mixture due to the dipole bonding by the partial charge of a specific functional group, and through their chemical structures, they can form a eutectic mixture at a molar ratio in the above range.
- the carnitine salicylate may preferably be a transparent phase without a precipitate when left still at a low temperature. More specifically, it may be that no precipitate is formed even if it is left at 0° C. for 3 weeks, 4 weeks, 5 weeks, or 6 weeks or more.
- the cosmetic composition may be in the form of a general emulsified formulation and a solubilized formulation.
- a lotion such as a softening lotion or nourishing lotion
- a lotion such as a facial lotion and body lotion
- a cream such as a nourishing cream, a moisture cream, an eye cream, an essence, a cosmetic ointment, a balm, a spray, a gel, a pack, a sunscreen , makeup base, liquid type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, cleansing agent such as cleansing foam, soap, body wash, and the like.
- the cosmetic includes a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetology such as other ingredients of
- the cosmetic formulation may include a relatively high concentration of the composition of the present invention in the case of a wash-off type cosmetic such as a makeup remover or a detergent in which the active ingredient stays on the skin within a short period of time.
- a wash-off type cosmetic such as a makeup remover or a detergent
- the composition of the present invention at a lower concentration than the wash-off type cosmetics. would be free to include.
- 0.01 to 20 parts by weight of carnitine salicylate (CA-SA), for example, 0.01 to 20 parts by weight, based on the total weight of the composition of the present invention , 0.01 to 1.2 parts by weight, 0.01 to 1.8 parts by weight, 0.01 to 2.5 parts by weight, 0.01 to 4.7 parts by weight, 0.1 to 7.3 parts by weight, 0.01 to 10 parts by weight, 1.2 to 20 parts by weight, or 1.8 to 10 parts by weight.
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- Each of the above-mentioned ingredients included in the cosmetic composition according to the present invention may be included in the cosmetic composition of the present invention within a range that does not exceed the maximum amount prescribed in the cosmetic safety standards for each country.
- the present invention provides a method for preparing a cosmetic composition comprising carnitine salicylate (CA-SA).
- the skin improvement comprising the step of treating the skin with a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient exhibits acne relief and keratin exfoliation effects, and at the same time soothes inflammation and erythema of the skin provides a way to alleviate
- CA-SA carnitine salicylate
- the method includes administering to a subject a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient, thereby exhibiting acne relief and exfoliating effects by improving skin, and at the same time soothing inflammation and erythema of the skin provides a way to alleviate
- CA-SA carnitine salicylate
- composition comprising carnitine salicylate (CA-SA) as an active ingredient for preparing a cosmetic for soothing inflammation and erythema of the skin while exhibiting the efficacy of alleviating acne and exfoliating the skin by improving the skin provides
- CA-SA carnitine salicylate
- preparing a mixture of carnitine and salicylic acid preparing carnitine salicylate (CA-SA) by stirring the mixture of carnitine and salicylic acid at 50° C. to 70° C.; and preparing a cosmetic composition by adding the carnitine salicylate (CA-SA).
- CA-SA carnitine salicylate
- the step of preparing the mixture of carnitine and salicylic acid may include adding purified water.
- the temperature is less than 50° C., the eutectic mixing is not sufficiently achieved, and if it exceeds 70° C., the eutectic mixture is broken, thereby reducing the effect of the eutectic mixture.
- the preparing of the carnitine salicylate may include homogenizing the mixture using a homogenizer. At this time, it may include a process of homogenizing the eutectic mixture until it becomes a colorless or light brown transparent phase. Thereafter, additional purification may be omitted.
- the components constituting the eutectic mixture are uniformly mixed under the homogenization conditions as described above, so that the skin improvement effect of the eutectic mixture as described above, hypoallergenicity to the skin, and excellent formulation stability can be realized.
- the liquid state and transparency are maintained even through a cooling process.
- the eutectic mixture prepared as described above is uniformly present without phase separation even at a very low temperature, for example, a temperature below 0° C., thereby maintaining a transparent liquid phase.
- the eutectic mixture may be maintained without breaking its bond even by repeating the solidification and melting processes.
- the step of preparing the carnitine salicylate is performed at a pH of 3.0 to 7.0. It is sufficiently dissolved within the acidity range and the efficacy can be maintained.
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- the upward shifted value was greatest in a, and it could be inferred that the functional group participating in the binding of carnitine salicylate (CA-SA) in salicylate was a carboxyl group.
- CA-SA carnitine salicylate
- the enhancement of the IR peak is observed due to vibration by -COOH and -OH groups.
- the positions of these main peaks are 1396-1385 (COOH), 1245 (CC), 1137-1195 (CCO, COH), 913 (C-COOH), and 625-634 (COH) cm -1 , and also ammonium Bands by groups are also characteristic.
- the peak represented by this group (CN + (CH 3 ) 3 ) is characterized by three bands at 970, 944 and 772 cm -1 .
- carnitine salicylate As shown in Table 2, when the efficacy of 10.0% of gluconolactone at pH 4.0 was relatively compared with 100%, carnitine salicylate (CA-SA) exhibited an exfoliating effect of 91.8%. On the other hand, the same amount of salicylate showed an exfoliation effect of 19.2%, carnitine 55.2%, and a simple mixture of carnitine and salicylate (CA+SA, MIX) of 56.5%. From the above results, it can be seen that carnitine salicylate (CA-SA) has a significant exfoliating effect even in weakly acidic with little stimulation.
- the cytotoxicity of carnitine salicylate was evaluated by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.
- MTT 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
- the cytotoxicity of salicylate, carnitine, and carnitine salicylate was evaluated by treating the material in rat macrophages Raw 264.7 and human fibroblasts (huamn fibroblast).
- Raw 264.7 is a representative cell used to measure NO inhibitory efficacy as an anti-inflammatory effect evaluation, and its cytotoxicity was evaluated. Cytotoxicity was assessed.
- Example 2 of Experimental Example 1-1 was used, and evaluation was performed based on the content of salicylic acid in the eutectic mixture, not the content of carnitine salicylate (CA-SA). . The results are shown in FIG. 2 .
- An anti-inflammatory effect confirmation test of carnitine salicylate was performed. Based on the results of Experimental Example 2-2, the anti-inflammatory effect by the NO inhibitory effect of salicylate, carnitine, and carnitine salicylate (CA-SA) at 10 ppm in which all materials do not show cytotoxicity was evaluated. 500ng/ml of LPS (lipopolysaccharide), an inflammatory substance, was treated, and 100 mMM of NG-monomethyl-L-arginine acetate (L-NMMA), a nitric oxide synthase (NOS) inhibitor, was treated as a positive control to confirm NO inhibition.
- LPS lipopolysaccharide
- L-NMMA NG-monomethyl-L-arginine acetate
- NOS nitric oxide synthase
- Example 2 of Experimental Example 1-1 was used. The results are shown in Table 3.
- carnitine salicylate (CA-SA) As shown in Table 3, 16.4% of salicylate, 0.0% of carnitine, 20.4% of a simple mixture of carnitine and salicylate (SA + CA), and 60.0% of carnitine salicylate (CA-SA) It showed NO inhibitory effect.
- SA + CA simple mixture of carnitine and salicylate
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- Example 5 Comparative Example 2 Comparative Example 3 Comparative Example 4 Furtherance CA-SA 0.5% SA 0.5% CA 0.5% SA 0.5% pH 5.5 5.5 6.0 2.7
- Example 5 when compared to the acne bacteria sterilization rate of each single component, Comparative Examples 2 and 3, under weakly acidic conditions, Example 5 was significantly higher, and despite the weak acidity, the pH was similar to Comparative Example 4 with the lowest pH. Therefore, it is judged that carnitine salicylate (CA-SA) according to the present invention can improve acne-prone skin without irritation by sufficiently removing acne bacteria even in weak acidity.
- CA-SA carnitine salicylate
- CA-SA carnitine salicylate
- 6 randomized subjects (age: 25 to 35 years old) who volunteered for the clinical trial were conducted.
- 5.0% DHA is applied to the forearm of the subject and maintained for 24 hours to stain the keratin.
- the stained area was evaluated using a colorimeter (CR-400, Konica Minolta, Japan), and 4 areas with the same staining level were selected.
- An aqueous solution of carnitine salicylate (CA-SA) (Example 6) and a base containing no sample (Comparative Example 5) are applied twice a day to the same site in the morning and evening for 14 days. In one place, it is compared with no application.
- the keratin exfoliation efficacy was evaluated by changing the brightness of the area stained with a colorimeter. The keratin exfoliation efficacy was evaluated as follows.
- Example 6 Comparative Example 5 deionized water To 100 To 100 Carnitine Salicylate (SA-CA) 5.00 - 1,2-Hexanediol 2.00 2.00 glycerin 8.00 8.00 1,3-butylene glycol 3.00 3.00 Cyclopentasiloxane 7.00 7.00 dimethicone 4.50 4.50 Polysorbate 60 (Twin 60) 1.50 1.50 Acrylate/C10-30 Alkylacrylate Crosspolymer 0.35 0.35 Tromethamine 0.35 0.35 Sum 100 100
- CA-SA carnitine salicylate
- Example 6 of Experimental Example 3-1 an erythema inhibition efficacy confirmation test was performed. Erythema index was evaluated before erythema induction, after erythema induction, 5 days after erythema induction, and 12 days after using the product for 9 volunteers (age: 25 to 35 years old) who volunteered to evaluate the erythema inhibitory effect. did. Apply 1% SDS diluted solution on the forearm for 24 hours to damage the skin barrier and induce erythema. The application was repeated twice a day on the same site in the morning and evening for 12 days. After 5 and 12 days, the erythema index was measured using a Mexameter (MX 18, Courage+Khazaka electronic GmbH, Germany), and the recovery rate of the erythema index was evaluated as follows.
- CA-SA carnitine salicylate
- a sensory evaluation test was performed using Example 6 of Experimental Example 3-1. To evaluate the sensory effect of keratin and skin soothing by applying a cosmetic composition containing carnitine salicylate (CA-SA), cosmetics are used every day. The evaluation was conducted for applicants with All of the volunteers used the cosmetics they normally use as they are, and additionally used a cosmetic composition including carnitine salicylate (CA-SA) according to the present invention in the first step after washing. The evaluation was conducted using a 5-point scale (5 points: very much improved, 4 points: felt an improvement, 3 points: no change felt, 2 points: felt worse, 1 point: very bad). The evaluation results are shown in Table 7 below.
- Test Items average score Soft feeling without irritation 4.32 skin erythema removal 3.50 Soothe skin immediately after use 3.67 Remove rough feeling from the skin 3.61 Overall product symbology 4.12
- the cosmetic composition according to the present invention contains carnitine salicylate (CA-SA) as an active ingredient, thereby exhibiting acne relief and keratin exfoliation efficacy as a skin improvement material by ion pairing of carnitine and salicylate in weakly acidic conditions.
- CA-SA carnitine salicylate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
CA:SA 몰비율 |
25℃ | 0℃ | |
실시예 1 | 3:1 | 이상없음 | 이상없음 |
실시예 2 | 2:1 | 이상없음 | 이상없음 |
실시예 3 | 1:1 | 이상없음 | 이상없음 |
실시예 4 | 1:2 | 이상없음 | 이상없음 |
비교예 1 | 1:3 | 3일 후 침전발생 | 1일 후 침전발생 |
각질 박리율 (%) | |
글로코노락톤 10%, pH 4 | 100.0 |
글로코노락톤 10%, pH 6 | 32.0 |
CA 2% | 55.2 |
SA 2% | 19.2 |
SA-CA 2% | 91.8 |
SA 1% + CA 1% | 56.5 |
NO 억제율 | |
음성대조군 | 0% |
L-MMMA (100 mΜ) | 62.2% |
SA 10 ppm | 16.4% |
CA 10 ppm | 0.0% |
SA-CA 10 ppm | 60.0% |
SA 10 ppm + CA 10 ppm | 20.4% |
실시예 5 | 비교예 2 | 비교예 3 | 비교예 4 | |
조성 | CA-SA 0.5% | SA 0.5% | CA 0.5% | SA 0.5% |
pH | 5.5 | 5.5 | 6.0 | 2.7 |
경과시간 | 실시예 5 | 비교예 2 | 비교예 3 | 비교예 4 |
1h | <100 | 5.02 x 105 | 4.96 x 105 | <100 |
3h | <100 | 1.75 x 105 | 4.96 x 105 | <100 |
6h | <100 | 2.00 x 103 | 3.44 x 105 | <100 |
24h | <100 | <100 | 2.04 x 105 | <100 |
성분명 | 실시예 6 | 비교예 5 |
탈이온수 | To 100 | To 100 |
카르니틴살리실레이트(SA-CA) | 5.00 | - |
1,2-헥산디올 | 2.00 | 2.00 |
글리세린 | 8.00 | 8.00 |
1,3-부틸렌글리콜 | 3.00 | 3.00 |
시클로펜타실록산 | 7.00 | 7.00 |
디메치콘 | 4.50 | 4.50 |
폴리소르베이트 60(트윈 60) | 1.50 | 1.50 |
아크릴레이트/C10-30 알킬아크릴레이트 크로스폴리머 | 0.35 | 0.35 |
트로메타민(Tromethamine) | 0.35 | 0.35 |
합계 | 100 | 100 |
시험 항목 | 평균 점수 |
자극 없이 부드러운 사용감 | 4.32 |
피부 홍반 제거 | 3.50 |
사용 직후 피부 진정 | 3.67 |
피부의 거친 느낌 제거 | 3.61 |
전반적인 제품 기호도 | 4.12 |
Claims (15)
- 카르니틴살리실레이트(CA-SA)를 유효성분으로 포함하는 화장료 조성물.
- 제1항에 있어서, 상기 화장료 조성물은 pH 4.0 내지 6.5인, 화장료 조성물.
- 제1항에 있어서, 상기 카르니틴살리실레이트(CA-SA)는 전체 조성물 100 중량부 기준 0.01 내지 20 중량부로 포함하는 화장료 조성물.
- 제1항에 있어서, 상기 카르니틴살리실레이트(CA-SA)는 카르니틴:살리실레이트=1 내지 6:2의 몰비율로 공융혼합된 것인, 화장료 조성물.
- 제1항에 있어서, 상기 카르니틴살리실레이트(CA-SA)는 0℃에서 4주간 정치했을 때 침전물이 없는 것인, 화장료 조성물.
- 제1항에 있어서, 상기 화장료 조성물은 피부 개선을 위한 것인, 화장료 조성물.
- 제6항에 있어서, 상기 피부 개선은 여드름 완화를 위한 것인, 화장료 조성물.
- 제6항에 있어서, 상기 피부 개선은 각질 박리 촉진을 위한 것인, 화장료 조성물.
- 제1항에 있어서, 상기 화장료 조성물은 피부 진정을 위한 것인, 화장료 조성물.
- 제9항에 있어서, 상기 피부 진정은 염증 완화를 위한 것인, 화장료 조성물.
- 제9항에 있어서, 상기 피부 진정은 홍반 완화를 위한 것인, 화장료 조성물.
- 카르니틴과 살리실산의 혼합물을 제조하는 단계;상기 혼합물을 50℃ 내지 70℃에서 교반하여 카르니틴살리실레이트(CA-SA)을 제조하는 단계; 및상기 카르니틴살리실레이트(CA-SA)를 첨가하여 화장료 조성물을 제조하는 단계;를 포함하는 화장료 조성물의 제조방법.
- 제12항에 있어서, 상기 카르니틴과 살리실산의 혼합물을 제조하는 단계는 정제수를 첨가하는 단계를 포함하는 화장료 조성물의 제조방법.
- 제12항에 있어서, 상기 카르니틴살리실레이트(CA-SA)를 제조하는 단계는 균질기를 이용하여 무색 또는 연갈색 투명상이 될 때까지 균질화하는 단계를 포함하는 화장료 조성물의 제조방법.
- 제12항에 있어서, 상기 화장료 조성물을 제조하는 단계는 카르니틴살리실레이트(CA-SA)를 전체 조성물 100 중량부 기준 0.01 내지 20 중량부로 첨가하는 단계를 포함하는, 화장료 조성물의 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22767498.3A EP4306100A1 (en) | 2021-03-08 | 2022-03-08 | Cosmetic composition comprising carnitine-salicylate as active ingredient |
CN202280019566.1A CN116981438A (zh) | 2021-03-08 | 2022-03-08 | 包含肉碱水杨酸盐作为有效成分的化妆料组合物 |
US18/280,829 US20240173232A1 (en) | 2021-03-08 | 2022-03-08 | Cosmetic composition comprising carnitine-salicylate as active ingredient |
JP2023554900A JP2024511323A (ja) | 2021-03-08 | 2022-03-08 | カルニチンサリシレートを有効成分として含む化粧料組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0030240 | 2021-03-08 | ||
KR20210030240 | 2021-03-08 | ||
KR20210170889 | 2021-12-02 | ||
KR10-2021-0170889 | 2021-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022191602A1 true WO2022191602A1 (ko) | 2022-09-15 |
Family
ID=83228144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/003302 WO2022191602A1 (ko) | 2021-03-08 | 2022-03-08 | 카르니틴살리실레이트를 유효성분으로 포함하는 화장료 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240173232A1 (ko) |
EP (1) | EP4306100A1 (ko) |
JP (1) | JP2024511323A (ko) |
KR (1) | KR20220126254A (ko) |
WO (1) | WO2022191602A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102640681B1 (ko) * | 2022-04-01 | 2024-02-27 | 주식회사 엘지생활건강 | 살리실산을 함유하는 공융 혼합물 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100095447A (ko) | 2007-12-27 | 2010-08-30 | 카오카부시키가이샤 | 여드름 피부용 피부 외용제 |
KR101017586B1 (ko) * | 2008-11-28 | 2011-02-28 | (주)아모레퍼시픽 | 피부 미백용 화장료 조성물 |
KR20120050437A (ko) * | 2009-06-25 | 2012-05-18 | 테트라, 시아 | 신규한 아세틸살리실산 염들 |
KR20130014519A (ko) * | 2010-03-31 | 2013-02-07 | (주)아모레퍼시픽 | 멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물 |
KR20130018739A (ko) * | 2010-03-03 | 2013-02-25 | 네오큐티스 에스아 | 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법 |
JP2014114289A (ja) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | 化粧料または皮膚外用剤 |
KR20170076091A (ko) | 2015-12-24 | 2017-07-04 | (주)아모레퍼시픽 | 살리실산 유도체와 그 제조방법 및 이를 함유하는 미백용 화장료 조성물 |
KR102307186B1 (ko) | 2021-05-03 | 2021-09-30 | 주식회사 네이처앤네이처 | 살리실산을 포함하는 화장료 조성물 |
-
2022
- 2022-03-08 EP EP22767498.3A patent/EP4306100A1/en active Pending
- 2022-03-08 KR KR1020220029610A patent/KR20220126254A/ko not_active Application Discontinuation
- 2022-03-08 WO PCT/KR2022/003302 patent/WO2022191602A1/ko active Application Filing
- 2022-03-08 JP JP2023554900A patent/JP2024511323A/ja active Pending
- 2022-03-08 US US18/280,829 patent/US20240173232A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100095447A (ko) | 2007-12-27 | 2010-08-30 | 카오카부시키가이샤 | 여드름 피부용 피부 외용제 |
KR101017586B1 (ko) * | 2008-11-28 | 2011-02-28 | (주)아모레퍼시픽 | 피부 미백용 화장료 조성물 |
KR20120050437A (ko) * | 2009-06-25 | 2012-05-18 | 테트라, 시아 | 신규한 아세틸살리실산 염들 |
KR20130018739A (ko) * | 2010-03-03 | 2013-02-25 | 네오큐티스 에스아 | 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법 |
KR20130014519A (ko) * | 2010-03-31 | 2013-02-07 | (주)아모레퍼시픽 | 멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물 |
JP2014114289A (ja) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | 化粧料または皮膚外用剤 |
KR20170076091A (ko) | 2015-12-24 | 2017-07-04 | (주)아모레퍼시픽 | 살리실산 유도체와 그 제조방법 및 이를 함유하는 미백용 화장료 조성물 |
KR102307186B1 (ko) | 2021-05-03 | 2021-09-30 | 주식회사 네이처앤네이처 | 살리실산을 포함하는 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20240173232A1 (en) | 2024-05-30 |
KR20220126254A (ko) | 2022-09-15 |
EP4306100A1 (en) | 2024-01-17 |
JP2024511323A (ja) | 2024-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022145663A1 (ko) | 락토바실러스 플란타룸 유산균 사균체 또는 상기 유산균의 배양물을 포함하는 피부 노화 방지 또는 개선용 화장료 조성물 | |
WO2020040442A1 (ko) | 수딩 크림 및 이의 제조 방법 | |
WO2015099274A1 (ko) | 탈분화 식물 프로토플라스트 내에 활성 물질이 인입된 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물 | |
WO2019103433A1 (ko) | 안정성이 개선된 신규 유사세라마이드 화합물 및 이를 포함하는 조성물 | |
KR20130108805A (ko) | 황금 누에 유래 물질을 유효성분으로 포함하는 화장료 조성물 | |
WO2017043670A1 (ko) | 유자 추출물을 함유하는 화장료 조성물 | |
WO2022191602A1 (ko) | 카르니틴살리실레이트를 유효성분으로 포함하는 화장료 조성물 | |
US6338854B1 (en) | Photoaging skin-care preparation and method of treating wrinkled skin | |
KR100377397B1 (ko) | 레티놀 및 표피성장인자를 함유하는 피부보호 화장료 조성물 | |
WO2019245229A1 (ko) | 7-데하이드로콜레스테롤, 콜레스테롤 및 스테아린산이 히알루론산-세라마이드 엔피 복합체의 내상에 봉입된 나노에멀젼을 함유하는 화장료 조성물 | |
JPH06199647A (ja) | 美白化粧料 | |
WO2012173382A2 (ko) | 탄시논ⅱa를 유효성분으로 함유하는 피부 외용제 조성물 | |
WO2016010283A1 (ko) | 납떼기콩 오일을 포함하는 조성물 | |
WO2019031790A1 (ko) | 세라마이드, 이의 유도체 및 목근피 추출물을 함유하는 피부 외용제 조성물 | |
WO2014175676A1 (ko) | 진세노사이드 rf를 함유하는 피부 외용제 조성물 | |
WO2012173383A2 (ko) | 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 | |
KR101418979B1 (ko) | 콜라겐 형성 촉진용 조성물 및 그를 이용한 화장품 | |
WO2017014597A1 (ko) | 오미자 종자 추출물을 포함하는 피부 미백 개선용 화장품 조성물 | |
WO2021251730A1 (ko) | 리젠타이드-034 및 리젠타이드-041을 포함하는 피부 보호 또는 주름 개선용 조성물 | |
WO2014178682A1 (ko) | 진세노사이드 rh4를 함유하는 피부 외용제 조성물 | |
JPH0859452A (ja) | 皮膚化粧料 | |
WO2021251727A1 (ko) | 리젠타이드-041 및 이를 포함하는 피부 상태 개선용 조성물 | |
WO2021251728A1 (ko) | 리젠타이드-012 또는 리젠타이드-013을 포함하는 피부 개선용 조성물 | |
WO2024025356A1 (ko) | 수크랄페이트를 포함하는 피부 재생용 화장료 조성물 | |
WO2024096553A1 (ko) | 피부 개선용 복합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22767498 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280019566.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18280829 Country of ref document: US Ref document number: 2023554900 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022767498 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022767498 Country of ref document: EP Effective date: 20231009 |